Companies · IQV
IQVIA
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Oct 27, 2026
IQVIA Q3 2026: 8.0% revenue growth and $32.6B backlog masked by $2.1B backlog methodology revision and rising restructuring spend
IQVIA delivered $4,428 million in Q3 2026 revenue, up 8.0% year-over-year, with both Commercial Solutions and Research & Development Solutions posting constant-currency growth above 7%. The headline result is qualified by two material disclosures: a $2.1 billion downward revision to R&D Solutions backlog — attributed to refined assessment criteria for inactive trials — reducing contracted backlog from $34.0 billion to $32.6 billion; and restructuring costs of $150 million in the first nine months of 2026, nearly double the $81 million incurred in the same period of 2025, signaling ongoing capacity rationalization that management expects to continue into 2027.
Tone: mixedRevenue
$16.3B
IQV 10-K · FY 2025
Employees
93,000
Revenue growth YoY
+5.9%
Headquarters
Durham, NC
Profile
IQV 10-K Item 1 · Feb 17, 2026IQVIA is a leading global provider of clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries. The company operates through three segments — Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions — serving over 10,000 clients in more than 100 countries. Its competitive differentiation rests on one of the largest proprietary healthcare datasets in the world, spanning more than 1.2 billion unique non-identified patient records and approximately 68 petabytes of unique proprietary data.
Read filing description ↓ Collapse description ↑
IQVIA is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise. We are committed to using artificial intelligence ('AI') responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 93,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, we are dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. We have one of the largest and most comprehensive collections of healthcare information in the world spanning sales, prescription, promotional and social media data, as well as medical claims, electronic medical records, and genomics data, including more than 1.2 billion comprehensive, longitudinal, unique non-identified patient records. Our scaled and growing information set contains approximately 68 petabytes of unique proprietary data sourced from approximately 150,000 data suppliers and covering over one million data feeds globally. Based on this data, we deliver information and insights on approximately 90% of the world's pharmaceuticals, as measured by 2024 sales. We combine our proprietary information assets with advanced analytics, transformative technology and domain expertise to develop clinical and commercial capabilities that enable us to grow our relationships with healthcare stakeholders throughout the life science's value chain.
Primary products
- IQVIA Connected Intelligence
- Healthcare-grade AI
- Real World Solutions
- Global Market Insight (MIDAS, Analytics Link, Disease Insights)
- IQVIA Health Data Catalog
- SaaS platforms for clinical and commercial operations
Business segments
End markets
Geographies
Named competitors
“While we believe no competitor provides the combination of geographical reach and breadth of our services, we generally compete in the countries in which we operate with other information, analytics, technology, services and consulting companies, as well as with the in-house capabilities of our clients.” Competitive position, as stated in the filing
Revenue commentary · FY 2025
Revenues increased $905 million, or 5.9%, in 2025 versus 2024, comprising approximately $737 million of constant currency growth, with contributions from all three segments.
The rest of IQV is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.